- Home
- TNGX vs CCO Comparison
TNGX vs CCO Comparison
Compare TNGX & CCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- CCO
- Stock Information
- Founded
- TNGX 2014
- CCO 1995
- Country
- TNGX United States
- CCO United States
- Employees
- TNGX N/A
- CCO N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- CCO Advertising
- Sector
- TNGX Health Care
- CCO Consumer Discretionary
- Exchange
- TNGX Nasdaq
- CCO Nasdaq
- Market Cap
- TNGX 723.2M
- CCO 735.6M
- IPO Year
- TNGX N/A
- CCO 2005
- Fundamental
- Price
- TNGX $8.76
- CCO $1.93
- Analyst Decision
- TNGX Strong Buy
- CCO Hold
- Analyst Count
- TNGX 6
- CCO 5
- Target Price
- TNGX $10.00
- CCO $1.88
- AVG Volume (30 Days)
- TNGX 2.1M
- CCO 3.8M
- Earning Date
- TNGX 11-06-2025
- CCO 11-06-2025
- Dividend Yield
- TNGX N/A
- CCO N/A
- EPS Growth
- TNGX N/A
- CCO N/A
- EPS
- TNGX N/A
- CCO 0.04
- Revenue
- TNGX $24,296,000.00
- CCO $1,538,895,000.00
- Revenue This Year
- TNGX $20.42
- CCO $6.16
- Revenue Next Year
- TNGX N/A
- CCO $4.01
- P/E Ratio
- TNGX N/A
- CCO $43.65
- Revenue Growth
- TNGX N/A
- CCO 31.61
- 52 Week Low
- TNGX $1.03
- CCO $0.81
- 52 Week High
- TNGX $9.70
- CCO $1.95
- Technical
- Relative Strength Index (RSI)
- TNGX 58.17
- CCO 75.64
- Support Level
- TNGX $8.85
- CCO $1.27
- Resistance Level
- TNGX $9.31
- CCO $1.95
- Average True Range (ATR)
- TNGX 0.56
- CCO 0.11
- MACD
- TNGX 0.08
- CCO 0.05
- Stochastic Oscillator
- TNGX 67.60
- CCO 96.32
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About CCO Clear Channel Outdoor Holdings Inc.
Clear Channel Outdoor Holdings Inc is a provider of out-of-home advertising solutions. The company offers advertisers an opportunity to reach mass audiences across various high-traffic public spaces, by using its diverse portfolio of assets including roadside billboards, street furniture, and airport displays. Its reportable segments are; America (U.S. operations excluding airports), Airports (U.S. and Caribbean airport operations), and Other. A majority of its revenue is generated from the America segment which generates revenue from the sale of advertising on printed and digital out-of-home advertising displays such as bulletins, posters, street furniture, and others. Geographically, the company generates maximum revenue from the United States followed by Singapore.